Top Markets
Coin of the day
Gilead Sciences, Inc. Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD
Rangering i aksjer #100
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations... Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
Aksjekurs
$150.78
Sist synkronisert: 2026-09-18
Markedsverdi
$187.20B
Endring (1 dag)
-0.08%
Endring (1 år)
32.15%
Land
US
Handel Gilead Sciences, Inc. (GILD)

Kategori

Antall utestående aksjer for Gilead Sciences, Inc. (GILD)
Antall utestående aksjer per June 2026: 1.24B
Ifølge Gilead Sciences, Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 1.24B. Ved slutten av December 2024 hadde selskapet 1.25B utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Gilead Sciences, Inc. (GILD) fra 2000 til 2026
Utestående aksjer ved utgangen av hvert år
År Utestående aksjer Endre
2026 (TTM) 1.24B -0.08%
2025 1.24B -0.24%
2024 1.25B -0.08%
2023 1.25B -0.56%
2022 1.26B -0.08%
2021 1.26B -0.08%
2020 1.26B -1.02%
2019 1.27B -2.16%
2018 1.30B -0.69%
2017 1.31B -2.39%
2016 1.34B -8.54%
2015 1.46B -3.81%
2014 1.52B -0.43%
2013 1.53B 0.92%
2012 1.51B -2.27%
2011 1.55B -9.48%
2010 1.71B -5.37%
2009 1.81B -1.75%
2008 1.84B -0.91%
2007 1.86B 1.19%
2006 1.84B 1.05%
2005 1.82B 5.17%
2004 1.73B 7.41%
2003 1.61B 2.84%
2002 1.56B 2.78%
2001 1.52B 4.47%
2000 1.46B 0.00%
Utestående aksjer for lignende selskaper eller konkurrenter
Selskap Utestående aksjer Forskjell Land
892.40M -28.21%
US
2.44B 96.31%
US
1.77B 42.48%
US
796.00M -35.96%
CH
0.00 -100.00%
US